Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens
| Autor: | Warangkana Munsakul, Pacharee Kantipong, Ploenchan Chetchotisakd, Sunee Sirivichayakul, Sorakij Bhakeecheep, Kathy Petoumenos, Jintanat Ananworanich, Somnuek Sungkanuparph, Supunnee Jirajariyavej, Virat Klinbuayaem, Wisit Prasithsirikul, Bernard Hirschel, Chureeratana Bowonwattanuwong, Torsak Bunupuradah, Kiat Ruxrungtham |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Cyclopropanes Male Genotype Anti-HIV Agents Human immunodeficiency virus (HIV) Etravirine HIV Infections Drug resistance medicine.disease_cause Nucleoside Reverse Transcriptase Inhibitor chemistry.chemical_compound Antiretroviral Therapy Highly Active Drug Resistance Viral Nitriles medicine Humans Pharmacology (medical) Nevirapine Pharmacology Reverse-transcriptase inhibitor business.industry Rilpivirine Virology Antiretroviral therapy Benzoxazines Pyridazines Stavudine Infectious Diseases Pyrimidines chemistry Lamivudine Alkynes Mutation HIV-1 RNA Viral Reverse Transcriptase Inhibitors Female business medicine.drug |
| Zdroj: | Antiviral therapy. 16(7) |
| ISSN: | 2040-2058 |
| Popis: | Background We studied prevalence of etravirine (ETR) and rilpivirine (RPV) resistance in HIV-1 subtype CRF01_AE infection with first-line non-nucleoside reverse transcriptase inhibitor (NNRTI) failure. Methods A total of 225 adults failing two nucleoside reverse transcriptase inhibitors (NRTIs) plus 1 NNRTI in Thailand with HIV RNA>1,000 copies/ml were included. Genotypic resistance results and HIV-1 subtype were interpreted by Stanford DR database. ETR resistance was calculated by the new Monogram weighted score (Monogram WS; ≥4 indicating high-level ETR resistance) and by DUET weighted score (DUET WS; 2.5–3.5 and ≥4 resulted in intermediate and reduce ETR response, respectively). RPV resistance interpretation was based on previous reports. Results Median (IQR) age was 38 (34–42) years, 41% were female and CDC A:B:C were 22%:21%:57%. HIV subtypes were 96% CRF01_AE and 4% B. Antiretrovirals at failure were lamivudine (100%), stavudine (93%), nevirapine (90%) and efavirenz (10%) with a median (IQR) duration of 3.4 (1.8–4.5) years. Median (IQR) CD4+ T-cell count and HIV RNA were 194 (121–280) cells/mm3 and 4.1 (3.6–4.6) log10 copies/ml, respectively. The common NNRTI mutations were Y181C (41%), G190A (22%) and K103N (19%). The proportion of patients with Monogram WS score ≥4 was 61.3%. By DUET WS, 49.8% and 7.5% of patients were scored 2.5–3.5 and ≥4, respectively. Only HIV RNA≥4 log10 copies/ml at failure was associated with both Monogram WS≥4 (OR 2.3, 95% CI 1.3–3.9; P=0.003) and DUET WS≥2.5 (OR 1.9, 95% CI 1.1–3.3; P=0.02). The RVP resistance-associated mutations (RAMs) detected were K101P (1.8%), Y181I (2.7%) and Y181V (3.6%). All patients with RPV mutation had ETR resistance. No E138R/E138K mutations were detected. Conclusions Approximately 60% of patients had high-level ETR resistance. The role of ETR in second-line therapy is limited in late NNRTI failure settings. RVP RAMs were uncommon, but cross-resistance between ETR and RVP was high. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|